Compare PRK & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | PRK | GPCR |
|---|---|---|
| Founded | 1908 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.8B |
| IPO Year | 1996 | 2023 |
| Metric | PRK | GPCR |
|---|---|---|
| Price | $188.30 | $41.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $184.00 | $103.17 |
| AVG Volume (30 Days) | 71.3K | ★ 701.3K |
| Earning Date | 04-24-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 19.21 | N/A |
| EPS | ★ 5.64 | N/A |
| Revenue | ★ $664,421,000.00 | N/A |
| Revenue This Year | $24.26 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $33.78 | ★ N/A |
| Revenue Growth | ★ 2.92 | N/A |
| 52 Week Low | $149.06 | $20.04 |
| 52 Week High | $215.00 | $94.90 |
| Indicator | PRK | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 32.70 |
| Support Level | $181.01 | $36.11 |
| Resistance Level | $188.04 | $56.63 |
| Average True Range (ATR) | 4.15 | 2.64 |
| MACD | -1.73 | -0.94 |
| Stochastic Oscillator | 3.45 | 11.23 |
Park National Corp is a diversified financial services company based in Newark, Ohio, consisting of 11 community banking divisions with more than 100 offices in Ohio and Kentucky. The company provides the following principal services: the acceptance of deposits for demand, savings and time accounts; commercial, industrial, consumer and real estate lending, including installment loans, credit cards (which are largely offered through a third party), home equity lines of credit and commercial leasing; trust and wealth management services; cash management; safe deposit operations; electronic funds transfers; and a variety of additional banking-related services.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.